
Free Daily Podcast Summary
by Decera Clinical Education
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
The most recent episodes — sign up to get AI-powered summaries of each one.
In this podcast episode, Craig Horbinski, MD, PhD, and Michael W. Ruff, MD, discuss the evolving diagnosis and management of H3 K27–altered diffuse midline glioma (DMG), emphasizing the importance of molecular testing, multidisciplinary collaboration, and emerging therapeutic strategies, including:The molecular and epigenetic characteristics of H3 K27–altered DMG and their implications for tumor classification and diagnosisChallenges in distinguishing DMG from other brainstem lesions and the importance of tissue biopsy, molecular profiling, and integrated pathology reportingEmerging diagnostic approaches, including cerebrospinal fluid analysis, cell-free DNA testing, and epigenomic profilingCurrent treatment strategies and emerging therapies, including radiotherapy, dordaviprone, and investigational CAR T-cell therapiesThe role of tissue stewardship, multidisciplinary coordination, and postmortem research in advancing diagnosis, selecting treatment, and understanding therapeutic responseGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.Presenters:Craig Horbinski, MD, PhDChairProfessor and Clinician Investigator of PathologyDepartment of Laboratory Medicine and PathologyMayo Clinic FloridaVice Chair, Translational Research, Neuro-Oncology CommitteeAlliance for Clinical Trials in OncologyJacksonville, FloridaMichael W. Ruff, MDAssistant Professor of Neurology and Medical OncologyMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/4iPzgQh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line setting. They highlight the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL.Presenters:Toby A. Eyre, MD, MBChBHematology ConsultantDepartment of HematologyOxford University Hospitals NHS TrustOxford, United KingdomTycel J. Phillips, MD, FASCOAssociate Professor of MedicineCity of Hope National Medical CenterDuarte, CaliforniaLink to full program: https://bit.ly/4k7VkrvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities.Presenters:Dai Chihara, MD, PhDAssociate ProfessorDepartment of Lymphoma and MyelomaUniversity of Texas MD Anderson Cancer CenterHouston, TexasJ.C. Villasboas B., MDAssistant Professor of Medicine and OncologyMayo Clinic College of MedicineConsultant, Division of Hematology, Lymphoma/Bone Marrow Transplant/Cellular Therapy GroupsDirector, Mayo Clinic Immune Monitoring Core LaboratoryRochester, MinnesotaLink to the full program:https://bit.ly/4zw8VOqGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencingEmerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapyOngoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZARBiomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXdSafety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitisGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.Presenters:Christine M. Bestvina, MDAssociate Professor of MedicineSection of Hematology/OncologyDivision of MedicineUniversity of Chicago MedicineChicago, IllinoisJoshua E. Reuss, MDThoracic Medical OncologistDirector of Thoracic Clinical ResearchAssociate Professor of MedicineGeorgetown Lombardi Comprehensive Cancer CenterWashington, DCLink to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including:Selecting quadruplet therapyOptimal use of bortezomibThe role of autologous stem cell transplantation in the quadruplet eraUse of MRD status to inform treatment decisionsMaintenance strategies Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program: https://bit.ly/4yTeLZDGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:HRR alterations and the mechanism of action of PARP inhibitorsGermline and somatic genomic testing and practical considerations for tissue and ctDNA testingPARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3Treatment selection across metastatic prostate cancer settings based on HRR alterationsPARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modificationPresenters:Neeraj Agarwal, MD, FASCOMedical Oncologist, Dana-Farber Cancer InstituteCo-Director, Prostate Cancer Program, Harvard Cancer ConsortiumThe Lank Center for Genitourinary OncologyBoston, MassachusettsEmmanuel S. Antonarakis, MDClark Endowed Professor of MedicineDirector of GU Oncology, Associate Director of TranslationDivision of Hematology, Oncology and TransplantationUniversity of Minnesota, Masonic Cancer CenterMinneapolis, MinnesotaLink to full program: https://bit.ly/4dtT35UGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program:https://bit.ly/3TZSmufGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomesEmerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisibFirst-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing Presenters: Hope S. Rugo, MD, FASCO Director, Women’s Cancer Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology University of California, San Francisco San Francisco, California Nerea Lopetegui-Lia, MD Assistant Professor Division of Medical Oncology, Breast Section Department of Internal Medicine The Ohio State University Columbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.Link to full program:https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

INTERLUDE: Cancer Stories with Dr. Teplinsky
Eleonora Teplinsky

Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Answers in CME

Core IM | Internal Medicine Podcast
A podcast exploring internal medicine through clinical reasoning, management decisions, and practical teaching points.

ICU Ed and Todd-Cast
Eddie and Todd

The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.

Thrive Through and Beyond Cancer
Season Johnson

This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.

The Genomics Lab
Olivia Grant

Health Matters
NewYork-Presbyterian

Frankly Speaking About Family Medicine
Discusses current topics and developments in primary care and family medicine.

The Antisocial Doctors Podcast
Sonia Singh MD & Rebecca Berens MD
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Decera Clinical Education Oncology Podcast in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Decera Clinical Education Oncology Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Decera Clinical Education.
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
Decera Clinical Education Oncology Podcast publishes weekly. Our AI generates a summary within hours of each new episode.
Decera Clinical Education Oncology Podcast covers topics including Science, Education, Courses, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.